Sugi Predict

Sugi Predict / Compounds / SCHEMBL2995906

SCHEMBL2995906

SCHEMBL2995906

CN(C)/C=C/C(=O)C1CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ DDB1 Q16531 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ USP2 O75604 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ USP30 Q70CQ3 3/20 0.35
▸ PTPN2 P17706 1/20 0.35
▸ PTPN1 P18031 1/20 0.35
▸ PTPN6 P29350 1/20 0.35
▸ NAMPT P43490 1/20 0.34
▸ RORC P51449 1/20 0.34
▸ TACR1 P25103 1/20 0.34
▸ CHRM2 P08172 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2995910 1.00 NR1H2 (0.43) NR1H2HPGDDDB1CRBNMEN1
SCHEMBL2285980 0.89 HPGD (0.51) HPGDMEN1ALDH1A1MAPTKMT2A
SCHEMBL2285975 0.89 HPGD (0.51) HPGDMEN1ALDH1A1MAPTKMT2A
SCHEMBL30364451 0.86 MEN1 (0.54) HPGDMEN1ALDH1A1MAPTKMT2A
SCHEMBL21348930 0.86 MEN1 (0.54) HPGDMEN1ALDH1A1MAPTKMT2A
SCHEMBL19194947 0.86 MEN1 (0.54) HPGDMEN1ALDH1A1MAPTKMT2A
SCHEMBL16827771 0.85 HPGD (0.54) HPGDMAPTKMT2AUSP2SMN1; SMN2
SCHEMBL29569186 0.85 NR1H2 (0.41) NR1H2HPGDDDB1CRBNMAPT
SCHEMBL16827768 0.85 HPGD (0.54) HPGDMAPTKMT2AUSP2SMN1; SMN2
SCHEMBL18418139 0.85 NR1H2 (0.41) NR1H2HPGDDDB1CRBNMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2026-05-26 — — US disclosed
US-20250345339-A1 DOSES AND REGIMENS OF HER2 INHIBITORS IAMBIC THERAPEUTICS INC (US) 2025-11-13 — — US disclosed
US-20250276983-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 IAMBIC THERAPEUTICS, INC. 2025-09-04 — — US disclosed
EP-4577549-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 Iambic Therapeutics, Inc. (US) 2025-07-02 — — EP disclosed
US-12145948-B2 Compounds and methods for modulating HER2 IAMBIC THERAPEUTICS, INC. (US) 2024-11-19 — — US disclosed
WO-2024153226-A1 PYRAZOLE-FUSED CYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京普祺医药科技股份有限公司 2024-07-25 — — WO disclosed
US-20240182494-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 IAMBIC THERAPEUTICS, INC. 2024-06-06 — — US disclosed
US-20240132521-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 IAMBIC THERAPEUTICS, INC. 2024-04-25 — — US disclosed
WO-2024044570-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 IAMBIC THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed
WO-2024044570-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 IAMBIC THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed
EP-2389382-B1 Amino-heterocyclic compounds used as pde9 inhibitors PFIZER (US) 2013-06-05 — — EP disclosed
US-20120329777-A1 Amino-Heterocyclic Compounds PFIZER INC. 2012-12-27 — — US disclosed
US-20120329777-A1 Amino-Heterocyclic Compounds PFIZER INC. 2012-12-27 — — US disclosed
US-20120329777-A1 Amino-Heterocyclic Compounds PFIZER INC. 2012-12-27 — — US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 — — US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 — — US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 — — US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 — — US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 — — US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250345339-A1 DOSES AND REGIMENS OF HER2 INHIBITORS ERBB2, EGFR, ERBB3 NR1H2 2708/4885HPGD 2095/4885DDB1 3354/4885
US-20120329777-A1 Amino-Heterocyclic Compounds PDE9A, PDE2A, PDE10A NR1H2 2730/4885HPGD 1306/4885DDB1 4011/4885
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PDE9A, PDE2A, PDE10A NR1H2 2730/4885HPGD 1306/4885DDB1 4011/4885
US-12145948-B2 Compounds and methods for modulating HER2 ERBB2, EGFR, ERBB3 NR1H2 997/4885HPGD 2342/4885DDB1 1820/4885
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP1, USP10 NR1H2 2913/4885HPGD 2931/4885DDB1 341/4885
US-20240182494-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 ERBB2, EGFR, ERBB3 NR1H2 997/4885HPGD 2342/4885DDB1 1820/4885
US-20240132521-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 ERBB2, EGFR, ERBB3 NR1H2 997/4885HPGD 2342/4885DDB1 1820/4885
US-20250276983-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 ERBB2, EGFR, ERBB3 NR1H2 997/4885HPGD 2342/4885DDB1 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.